Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims closely align with core label statements asserting that Keytruda is pembrolizumab and is indicated for melanoma and NSCLC. However, numerous historical patent dates, exclusivity details, and litigation history are not present in the FDA label and are therefore unsupported. Safety, dosing, contraindications, and other critical label sections are not addressed in the claims, contributing to overall misalignment.
Category Scores
Accurate Statements
Keytruda is pembrolizumab.
12.1; 1.1; 1.2
Keytruda is an immunotherapy medication used to treat various types of cancer.
12.1; 1.1; 1.2
Keytruda is used to treat advanced melanoma.
1.1
Keytruda is used to treat non-small cell lung cancer.
1.2
Unsupported Statements
Keytruda was first approved by the FDA in 2014 for the treatment of advanced melanoma.
Not present in the supplied label sections.
The initial patent for Keytruda was filed in 2006.
Not present in the supplied label sections.
The initial patent for Keytruda was granted in 2011.
Not present in the supplied label sections.
The patent is set to expire in 2028.
Not present in the label.
The patent exclusivity period is 14 years.
Not present in the label.
The expiration date means that other companies will be able to market generic versions after 2028.
Not present in the label.
In 2019, Mylan Pharmaceuticals filed a lawsuit challenging the validity of the Keytruda patent.
Not present in the label.
The lawsuit claimed that the patent was invalid due to prior art and that the patent holder had failed to adequately disclose the invention.
Not present in the label.
The lawsuit was dismissed.
Not present in the label.
The patent remains valid.
Not present in the label.
Contradictions
Important Omissions
Safety information such as boxed warnings for immune-mediated adverse reactions, dosing safety, pregnancy risk, pediatric safety, contraindications, and potential drug interactions.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Claims focus on mechanism and select indications; no safety details are provided, but this alone does not indicate patient risk—it's an omission in labeling context.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Patent/history and broader regulatory context are not part of the FDA label and were inappropriately claimed as label content.
Suggested Improvement
Limit claims to FDA-approved labeling content; cite exact label sections (e.g., 12.1, 1.1, 1.2). Include safety-related items (boxed warnings, dosing, contraindications, pregnancy, pediatric considerations) if they are discussed in the source response.